Point72 Asset Management
MREO

Point72 Asset Management’s Mereo BioPharma MREO Stock Holding History

Point72 Asset Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59,200
Closed -$160K – 2546
2025
Q2 		$160K Buy
59,200
+23,384
+65% +$56.4K ﹤0.01% 2021
2025
Q1 		$80.6K Buy
+35,816
New +$101K ﹤0.01% 1937
2024
Q2 		– Sell
-1,900
Closed -$6.27K – 2235
2024
Q1 		$6.27K Buy
+1,900
New +$6.43K ﹤0.01% 2108
2022
Q4 		– Sell
-9,829,354
Closed -$8.46M – 1693
2022
Q3 		$8.46M Sell
9,829,354
-206,616
-2% -$253K 0.03% 554
2022
Q2 		$11.2M Sell
10,035,970
-1,459,030
-13% -$1.13M 0.05% 483
2022
Q1 		$12.9M Buy
11,495,000
+885,000
+8% +$1.14M 0.05% 445
2021
Q4 		$17M Buy
10,610,000
+635,000
+6% +$1.27M 0.07% 371
2021
Q3 		$24.1M Sell
9,975,000
-132,189
-1% -$350K 0.11% 259
2021
Q2 		$32M Buy
10,107,189
+1,830,689
+22% +$6.14M 0.14% 185
2021
Q1 		$27.9M Buy
+8,276,500
New +$29.3M 0.13% 200
2020
Q4 		– Sell
-284,469
Closed -$745K – 1059
2020
Q3 		$745K Sell
284,469
-90,531
-24% -$265K ﹤0.01% 810
2020
Q2 		$1.15M Buy
+375,000
New +$662K 0.01% 666

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's MREO Position: Q3 2025 in Review

Point72 Asset Management sold out of Mereo BioPharma (MREO) in Q3 2025, closing a stake of 59,200 shares — an estimated $160K sold.

Point72 Asset Management first reported a position in MREO in Q2 2020 and held it in 12 quarters. The position peaked at $32M in Q2 2021. 84 funds tracked by Wall St. Rank hold MREO as of Q3 2025.

  • Point72 Asset Management reported no remaining Mereo BioPharma position as of Q3 2025 after selling out during the quarter.
  • Point72 Asset Management sold 59,200 Mereo BioPharma shares in Q3 2025, an estimated $160K.
  • Point72 Asset Management first reported a position in Mereo BioPharma in Q2 2020 and held it in 12 quarters.
  • Point72 Asset Management's Mereo BioPharma position peaked at $32M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.